AOP-208
AOP-208, also known as LB-208, is a selective serotonin 5-HT 1B receptor antagonist which is under development for the treatment of lymphoma, solid tumors, acute myeloid leukemia, and myelodysplastic syndromes.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
AOP-208, also known as LB-208, is a selective serotonin 5-HT 1B receptor antagonist which is under development for the treatment of lymphoma, solid tumors, acute myeloid leukemia, and myelodysplastic syndromes. It is taken orally. The drug is being developed by AOP Orphan Pharmaceuticals AG and Leukos Biotech.
As of October 2024, it is in phase 1 clinical trials for lymphoma and solid tumors and is in the preclinical research stage of development for acute myeloid leukemia and myelodysplastic syndromes. The chemical structure of AOP-208 does not yet appear to have been disclosed.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1336146627 under CC BY-SA 4.0; modifications have been made.